Media Alert – COVID-19 New Findings: FLCCC Alliance News Conference

Prophylaxis & Treatment Protocols for Covid-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

A team of highly published, ICU critical care physician/scholars have conducted a comprehensive analysis of the rapidly accumulating scientific study data from centers around the world supporting the efficacy of a repurposed oral medication. The team will announce the results of its research that demonstrates the consistent, reproducible, and high effectiveness of this safe, inexpensive, and globally available oral agent in both the prevention and treatment of COVID-19.  

The physicians will also call for immediate action from national health authorities to conduct a swift review of these data; with the goal of then being able to issue an urgent public health alert with recommendations for widespread distribution of this therapeutic that can significantly impact the current  surge in COVID-19 infections.  

When: Friday morning, December 4, at 10:30 am CST  

Where: United Memorial Medical Center in Houston, Texas  

510 West Tidwell Road, 77091  

Webinar registration: https://us02web.zoom.us/webinar/register/WN_TrQi8iUvTeC_Gf_s6Z2jqA 

Who: Joe Varon, M.D., FCCP, FCCM 

− Chief of Staff and Chief of Critical Care Services at United Memorial Medical Center and United General Hospital  

− Former Chief of Staff at University General Hospital 

− Professor of Acute and Con+nuing Care at the University of Texas Health Science Center, CAP, Department of  Medicine, Baylor College of Medicine  

− Professor of Medicine and Surgery, UAT, UABC, UNE, USON, UPAEP, Mexico  

Paul Marik, M.D., FCCM, FCCP  

− Board certified in Internal Medicine, Cri+cal Care Medicine, Neurocritical Care and Nutrition Science 

− Professor of Medicine (with tenure) and Chief of the Division of Pulmonary and Critical Care Medicine, at Eastern Virginia Medical School in Norfolk, Virginia  

− Author of more than 450 peer-reviewed journal articles, 80 book chapters, and four critical care books  

− Cited over 36,000 times in peer-reviewed publications 

− Delivered more than 350 lectures at international conferences and visiting professorships  

− Recipient of numerous teaching awards including ‘National Teacher of the Year’ by the American College of Physicians in 2017  

− The second most published critical care doctor in the world  

Pierre Kory, M.D., M.P.A.  

− Associate Professor of Medicine, Board Certified in Critical Care, Pulmonary Diseases, and Internal Medicine  

− Advocate Aurora Critical Care Service, Aurora St. Luke’s Medical Center, Milwaukee,WI  

− Former Chief of the Critical Care Service and Medical Director of the Trauma and Life Support Center at the University of Wisconsin  

− Senior editor of the best-selling textbook, ‘Point of Care Ultrasound’ now translated into 6 languages,  

published expert on the use of therapeutic hypothermia after cardiac arrest and the efficacy of intravenous  

ascorbic acid in the treatment of severe infections and septic shock 

 

Additional Info  

Drs. Varon, Marik, and Kory are founding members of the Frontline COVID-19 Critical Care Alliance (FLCCC) a 501(c)(3) nonprofit organization formed by a group of Critical Care physician/scholars — with the academic  support of allied physicians from around the world — formed in March 2020, to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. The FLCCC doctors  share decades of experience in hospital ICUs and have published more than 1,000 scientific studies in leading medical journals. (The FLCCC is not associated in any way with the group called ‘America’s FrontlineDoctors’.) 

If you want to know more about the FLCCC Alliance please regard our “About” section on www.flccc.net, in  particular the “FLCCC Alliance Story.”  

In addition our home page contains Scientific Reviews and many links to scientific studies that provide the medical evidence in support of our prophylaxis & treatment protocols for Covid-19.  

FLCCC Alliance – Mission Statement and ObjecOves  

Formed by leading critical care specialists in March 2020, at the beginning of the Coronavirus pandemic,  the ‘Front Line COVID-19 Critical Care Alliance’ is now a 501(c)(3) non-profit organization dedicated to developing highly effective treatment protocols to prevent the transmission of COVID-19 and to improve  the outcomes for patients ill with the disease.  

We are dedicated to  

− Reviewing all emerging published medical literature on COVID-19 from in-vitro, animal, clinical, and epidemiologic studies.  

− Developing effetive treatment protocols for COVID-19 that evolve by incorporating newly identified, applicable therapeutic and pathophysiologic insights.  

− Educating physicians on safe and effective treatment approaches to all phases of COVID-19, from disease prevetion strategies to the use of our combination-based therapy protocols in both early stage (I-MASK+) and hospitalized patients (MATH+).  

− Improving outcomes for people impacted by COVID-19 disorders through preventive and treatment strategies designed to optimize health.  

− Teaching the public ways to prevent transmission of the virus and to advocate for the best possible care.  

− Coordinating and accelerating the formation of research studies that will support effective prevention and therapeutic treatments for all impacted by COVID-19  

We accomplish these goals by sponsoring high quality medical education for both the public and health care providers, via the publication of scientific manuscripts, media interviews, and medical lectures for medical providers and the public. 

For more information about the FLCCC Alliance, the I-Mask+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19, please visit www.flccc.net




Filters close

Showing results

110 of 5584
Released: 7-May-2021 1:40 PM EDT
There is no evidence that vaccines could cause harm to people who have recovered from COVID-19
Newswise

An article published by Robert F. Kennedy Jr.’s anti-vaccination organization and widely shared on social media questions the need of vaccinating those who’ve already recovered from COVID-19. The article says there’s a "potential risk of harm, including death" in getting the vaccines. We report this claim as false. There is no evidence that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events.

Newswise: Abbott.jpg
Released: 7-May-2021 1:00 PM EDT
FSU expert available to discuss intellectual property and COVID-19 vaccines
Florida State University

By: Bill Wellock | Published: May 7, 2021 | 11:55 am | SHARE: President Joe Biden has expressed his support for a World Trade Organization proposal to waive intellectual property rights for COVID-19 vaccines.Florida State University law professor Frederick Abbott, the Edward Ball Eminent Scholar Professor of International Law, is available to comment on international intellectual property rights and global economic issues around the proposal.

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 1:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 11:15 AM EDT
Asthma attacks plummeted among Black and hispanic/latinx individuals during the COVID-19 pandemic
Brigham and Women’s Hospital

Asthma attacks account for almost 50 percent of the cost of asthma care which totals $80 billion each year in the United States

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 9:00 AM EDT
Navigating the COVID-19 crisis to prevent pressure injuries: Learning health system helped one hospital adapt and update care in real time
Wolters Kluwer Health: Lippincott

Early in the COVID-19 pandemic, healthcare systems scrambled to modify patient care processes – particularly when it came to strategies aimed at reducing the risk of hospital-related complications. A look at how one hospital applied its learning health system (LHS) framework to respond to a COVID-19-related increase in hospital-acquired pressure injuries (HAPIs) is presented in the May/June Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Released: 7-May-2021 8:55 AM EDT
Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Texas Tech University

EviroTech LLC announced today (May 7) a $4 million investment into the company by 1701 Ventures GmbH of Göttingen, Germany, which will allow EviroTech to complete the final design, production startup and market introduction of its Ultra-Fast COVID-19 detection sensor.

Released: 7-May-2021 7:05 AM EDT
Rutgers Recruiting Participants for Pfizer COVID-19 Pediatric Vaccine Clinical Trial
Rutgers University-New Brunswick

Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children ages 6 months to 11 years. This is the third time Rutgers has served as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it conducted trials for Moderna and Johnson & Johnson.


Showing results

110 of 5584

close
2.79489